Industry Growth Opens Doors for Pharma Innovators

With the global psychedelic drugs market projected to reach A$14 billion by 2032, and the medical cannabis sector already generating more than A$3 billion annually across Australia, Germany, the UK and the EU, Bioxyne Limited (ASX:BXN) is growing revenues as it meets increased demand.

The company announced an upgraded FY2025 revenue forecast, rising from $25 million to $28 million, driven by rapid growth in its pharmaceutical operations and expanded market traction in Europe.

Momentum Behind Guidance Upgrade

Bioxyne’s management attributes the upgraded forecast to sustained performance across its Australian pharmaceutical manufacturing division and the accelerating rollout of psychedelic products through its wholly owned subsidiary, Breathe Life Sciences (BLS).

The Company reported H1 FY2025 revenue of $12.6 million—marking a 267% increase on the previous half. H2 revenue is expected to hit $15.4 million, up 226% compared to the same period last year.

Growth in the Australian market continues to outperform expectations pointing to pharmaceutical manufacturing and supply as the major contributor to its FY2025 result.

Expanded Manufacturing of Psychedelic Medicines

Bioxyne is positioning itself at the forefront of the alternative therapeutics sector through BLS, which leads the Australian market in the manufacture of MDMA, Psilocybin, and medicinal cannabis products.

The Company confirmed that BLS’s MDMA capsules (BLSMD40 and BLSMD100) are scheduled to enter commercial batch production in July, marking a significant step in its psychedelic commercialisation strategy.

Development is progressing on schedule, and July batch production will be a key milestone for the company’s MDMA pipeline.

Global Markets Offer Multi-Billion Dollar Potential

Bioxyne operates in international markets with an estimated combined annualised revenue opportunity exceeding A$3 billion. Australia and Germany each represent roughly A$1 billion in annual revenue potential, with the UK and EU contributing a further A$1 billion.

In addition to these cannabis-focused markets, Bioxyne cited external data projecting A$3.5 billion in annual spend on psychedelic PTSD treatments and A$5 billion on treatment-resistant depression therapies, signalling robust demand ahead.

FY2026 Outlook Remains Positive

With FY2025 shaping up to be a record year, Bioxyne is already looking to FY2026, where further expansion is expected across both Australian and international markets.

The Company said it anticipates delivering FY2026 revenue guidance in August, following deeper engagement in the UK, Germany, and other EU jurisdictions.

About Bioxyne and Breathe Life Sciences

Bioxyne Limited is an Australian pharmaceutical and consumer health company, focused on developing innovative medicines and active pharmaceutical ingredients. Its subsidiary, Breathe Life Sciences, operates as a GMP-licensed manufacturer and distributor of controlled substances – including medicinal cannabis, MDMA, and Psilocybin – across Australia, Japan, the UK, and the EU.

The vertically integrated BLS business spans licensed manufacturing, import/export, wholesale, contract manufacturing, and direct-to-consumer retail through brands like Dr Watson. BLS sources raw materials globally and is expanding its footprint in alternative therapeutics and investigational medicines.

With strong foundations in Australia and growing traction overseas, Bioxyne is advancing its mission to lead in next-generation psychotropic and pharmaceutical therapies.